The slides that support the webinar presentation ‘An industry perspective on common practise in forced degradation studies of biopharmaceuticals’, presented on 15 June 2021.
environmental monitoring in drug product (EMinDP)
Viewing related articles
Environmental Monitoring (EM): A harmonized risk-based approach to selecting monitoring points and defining monitoring plans
Nov 2020 | Deliverable, Environmental Monitoring in Drug Product, Fill Finish, POI - Fill Finish, Publication
The purpose of an EM risk assessment (RA) is to provide information to determine how to distribute monitoring to best verify that processes are operating under control. This step-by step guidance covers the EM RA process and provides recommendations on monitoring sites and methods based on the relative probability of contamination industry guidance addresses these needs and attempts to capture best practices in a useable ‘toolkit’ format. The guide incorporates good practices from biopharmaceutical manufacturers and adheres to current regulatory guidelines.
Environmental monitoring (EM): Risk assessment template
Feb 2019 | COVID 19, Environmental Monitoring in Drug Product (EMinDP), Fill Finish, POI - Fill Finish
This Excel spreadsheet tool compliments the guidance document ‘Environmental monitoring: harmonized risk-based approach to selecting monitoring points and defining monitoring plans’. This allows the user to assess a room against six factors, the amenability of equipment and surfaces to cleaning and sanitization, personnel presence and flow, material flow, proximity to open product or exposed direct product contact material, the need for interventions/operations and their complexity, frequency of intervention and score them